LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Wojciech Jurczak(Jagiellonian University), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Minal Barve(Mary Crowley Cancer Research Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Donald E. Tsai(University of Pennsylvania), Binoj C. Nair(Eli Lilly (United States)), Constantine S. Tam(The Alfred Hospital), James N. Gerson(UPMC Hillman Cancer Center), John M. Pagel(University of Washington), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Toby A. Eyre(Oxford University Hospitals NHS Trust), Matthew S. Davids(Dana-Farber Cancer Institute), Chan Y. Cheah(The University of Western Australia), Stephen J. Schuster(Hospital of the University of Pennsylvania), Bita Fakhri(University of California, San Francisco), Alvaro J. Alencar(University of Miami), Paolo Ghia(Vita-Salute San Raffaele University), Nirav N. Shah(Medical College of Wisconsin), Justin Taylor(Medical University of South Carolina), William G. Wierda(University of Maryland, Baltimore), Jessica Chen(Loxo Oncology at Lilly (United States)), David Lewis(University Hospitals Plymouth NHS Trust), Manish R. Patel(Sarah Cannon), Nora Ku(Loxo Oncology at Lilly (United States)), Nicole Lamanna(Memorial Sloan Kettering Cancer Center)
Cited by 26
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k